Abdominal pain endpoints currently recommended by the FDA and EMA for adult patients with irritable bowel syndrome may not be reliable in children

Neurogastroenterology and Motility

Volumn 27, Issue 6, 2015, Pages 849-855

  Saps, M ^a   Lavigne, John V ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Clinicially significant change; Functional abdominal pain; Irritable bowel syndrome; Patient reported outcomes

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT;

ABDOMINAL PAIN; ANALGESIA; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EUROPEAN MEDICINES AGENCY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TEST RETEST RELIABILITY; VISUAL ANALOG SCALE; ADOLESCENT; COMPLICATION; IRRITABLE BOWEL SYNDROME; PAIN MEASUREMENT; PROCEDURES; REPRODUCIBILITY; UNITED STATES;

ABDOMINAL PAIN; ADOLESCENT; AMITRIPTYLINE; ANALGESICS, NON-NARCOTIC; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PAIN MEASUREMENT; PATIENT OUTCOME ASSESSMENT; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84929654152     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12559     Document Type: Article

References (20)

1. Devanarayana NM, Mettananda S, Liyanarachchi C, Nanayakkara N, Mendis N, Perera N, Rajindrajith S. Abdominal pain-predominant functional gastrointestinal diseases in children and adolescents: prevalence, symptomatology, and association with emotional stress. J Pediatr Gastroenterol Nutr 2011; 53: 659-65.
2. Saps M, Nichols-Vinueza DX, Rosen JM, Velasco-Benitez CA. Prevalence of functional gastrointestinal disorders in Colombian school children. J Pediatr 2014; 164: 542-545.e541.
3. Saps M, Seshadri R, Schaffer G, Sztainberg M, Marshall B, Di Lorenzo C. A prospective school-based study of abdominal pain and other common somatic complaints in children. J Pediatr 2009; 154: 322-6.
4. van der Veek SMC, Derkx HHF, de Haan E, Benninga MA, Boer F. Abdominal pain in Dutch schoolchildren: relations with physical and psychological comorbid complaints in children and their parents. JPGN 2010; 51: 481-7.
5. Food and Drug Administration: Guidance for Industry. Irritable bowel syndrome-clinical evaluation of drugs for treatment. 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryinformation/Guidances/UCM205269.pdf.
6. European Medicines Agency. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500146176.pdf.
7. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997; 50: 869-79.
8. Chogle A, Sztainberg M, Bass L, Youssef NN, Miranda A, Nurko S, Hyman P, Cocjin J et al. Accuracy of pain recall in children. J Pediatr Gastroenterol Nutr 2012; 55: 288-91.
9. Mohammad S, Di Lorenzo C, Youssef NN, Miranda A, Nurko S, Hyman P, Saps M. Assessment of abdominal pain through global outcomes and recent FDA recommendations in children. Are we ready for change?. J Pediatr Gastroenterol Nutr 2013; 58: 46-50.
10. Saps M, Youssef NN, Miranda A, Nurko S, Hyman P, Cocjin J, Di Lorenzo C. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009; 137: 1261-9.
11. Stinson JN, Kavanaugh T, Yamada J, Gill N, Stevens B. Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. Pain 2006; 125: 143-57.
12. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. 2): 1169-77.
13. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
14. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ruegg P, Ligozio G, Lefkowitz M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
15. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002; 24: 547-61.
16. Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. The Spine Journal 2007; 7: 541-6.
17. Jacobson N, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-9.
18. McLeod BD, Weisz JR, Wood JJ. Examining the association between parenting and childhood depression: a meta-analysis. Clin Psychol Rev 2007; 27: 986-1003.
19. Crosby RD, Kolotkin RL, Williams R. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407.
20. Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218-28.